Access

Letters to Editor

Nature Medicine 7, 383 - 385 (2001)
doi:10.1038/86397

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

David Lawrence1, Zahra Shahrokh1, Scot Marsters1, Kirsten Achilles1, Danny Shih1, Barbara Mounho1, Kenneth Hillan1, Klara Totpal1, Laura DeForge1, Peter Schow1, Jeffrey Hooley1, Steve Sherwood1, Roger Pai1, Susan Leung1, Lolo Khan1, Brian Gliniak2, Jeanine Bussiere2, Craig A. Smith2, Stephen S. Strom3, Sean Kelley1, Judith A. Fox1, Deborah Thomas1 & Avi Ashkenazi1,4

  1. Genentech Incorporated, South San Francisco, California, USA
  2. Immunex Corporation, Seattle, Washington, USA
  3. University of Pittsburgh, Pittsburgh, Pennsylvania, USA
  4. e-mail: aa@gene.com

Apo2L/TRAIL (Apo2 ligand or tumor necrosis factor (TNF)-related apoptosis-inducing ligand) was discovered by its sequence homology to TNF and CD95L (refs. 1,2).